ProNAi Therapeutics, Inc. (NASDAQ:SRRA) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Friday.

Several other brokerages have also recently issued reports on SRRA. Jefferies Group LLC reaffirmed a “hold” rating on shares of ProNAi Therapeutics in a research note on Thursday, July 27th. Zacks Investment Research cut shares of ProNAi Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. ProNAi Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.25.

Shares of ProNAi Therapeutics (NASDAQ SRRA) remained flat at $1.58 on Friday. 167,078 shares of the stock traded hands. ProNAi Therapeutics has a one year low of $1.10 and a one year high of $2.01. The firm’s market capitalization is $82.58 million. The company’s 50-day moving average is $1.48 and its 200-day moving average is $1.37.

ProNAi Therapeutics (NASDAQ:SRRA) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. Equities analysts forecast that ProNAi Therapeutics will post ($0.91) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “ProNAi Therapeutics, Inc. (SRRA) Raised to Sell at ValuEngine” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/01/pronai-therapeutics-inc-srra-raised-to-sell-at-valuengine.html.

A number of hedge funds have recently made changes to their positions in SRRA. Nexthera Capital LP acquired a new stake in shares of ProNAi Therapeutics during the first quarter valued at about $612,000. Perceptive Advisors LLC acquired a new stake in shares of ProNAi Therapeutics during the first quarter valued at about $5,667,000. Sabby Management LLC acquired a new stake in shares of ProNAi Therapeutics during the first quarter valued at about $2,672,000. VHCP Management II LLC acquired a new stake in shares of ProNAi Therapeutics during the first quarter valued at about $200,000. Finally, Frazier Management LLC acquired a new stake in shares of ProNAi Therapeutics during the first quarter valued at about $12,412,000. 55.72% of the stock is owned by institutional investors.

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Receive News & Stock Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related stocks with our FREE daily email newsletter.